DA Davidson Issues Pessimistic Forecast for USANA Health Sciences (NYSE:USNA) Stock Price

USANA Health Sciences (NYSE:USNA - Free Report) had its price target cut by DA Davidson from $38.00 to $36.00 in a research report report published on Thursday,Benzinga reports. They currently have a neutral rating on the stock. DA Davidson also issued estimates for USANA Health Sciences' Q1 2025 earnings at $0.83 EPS, Q1 2025 earnings at $0.76 EPS, Q1 2025 earnings at $0.76 EPS, FY2025 earnings at $2.57 EPS, FY2025 earnings at $2.38 EPS, FY2025 earnings at $2.38 EPS, FY2026 earnings at $2.59 EPS and FY2026 earnings at $2.68 EPS.

A number of other equities research analysts have also recently weighed in on the stock. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th. Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th.

USANA Health Sciences Trading Up 1.3 %

USANA Health Sciences stock traded up $0.38 during mid-day trading on Thursday, hitting $29.97. The company's stock had a trading volume of 287,508 shares, compared to its average volume of 169,645. The stock's fifty day moving average is $33.42 and its two-hundred day moving average is $36.47. The firm has a market capitalization of $571.21 million, a PE ratio of 10.59, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. USANA Health Sciences has a 1 year low of $27.71 and a 1 year high of $50.32.

Remove Ads

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.15. The business had revenue of $213.61 million during the quarter, compared to analysts' expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, equities analysts expect that USANA Health Sciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in USNA. Pzena Investment Management LLC raised its holdings in USANA Health Sciences by 3.6% in the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock valued at $39,015,000 after acquiring an additional 37,466 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of USANA Health Sciences by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock valued at $27,751,000 after purchasing an additional 55,059 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of USANA Health Sciences by 8.8% during the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company's stock worth $21,247,000 after purchasing an additional 47,745 shares during the last quarter. State Street Corp grew its stake in shares of USANA Health Sciences by 0.6% during the third quarter. State Street Corp now owns 435,164 shares of the company's stock worth $16,501,000 after purchasing an additional 2,782 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of USANA Health Sciences by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 301,949 shares of the company's stock worth $10,839,000 after purchasing an additional 4,829 shares in the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.